S. 1414 · Senate bill · 119th Congress
Expedited Access to Biosimilars Act Introduced Apr 10, 2025 Reported by committee Jul 27, 2026 Passed the Senate (not yet) Passed the House (not yet) Law (not yet) Latest action, Jul 27, 2026 : Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
What it would change (1) About this text
1 section of the Code · 13 changes asked for
Text: reported in Senate Reported The text a committee sent back to its chamber, often with changes, recommending a vote. , Jul 27, 2026
The other version Official text on Congress.gov
Written by AIWhat this bill would change in the Code
For biosimilar applications (copies of already-licensed biological products), the bill would replace the current requirement of a clinical study with a narrower set of data. Applicants would give an assessment of pharmacokinetics (how the body processes the drug) and immunogenicity (immune response), and a clinical study only if the Secretary requires one. The Secretary could require a study of pharmacodynamics or efficacy only by written determination, due at the development-meeting minutes or within 60 days of the application, and changeable only by agreement or with written justification. It would also repeal the rule that the reference product's review division reviews the application.
This is the note on the one section the bill would change. It covers only changes to the Code. No person has checked it, and it can be wrong. The changes themselves are what the bill would do. About these notes
Sections are cited like “7 U.S.C. § 2012”: title Title One of the 54 subject areas the Code is divided into, such as Title 7 (Agriculture) or Title 26 (taxes). A title is split into chapters. 7 of the United States Code U.S.C. (United States Code) The United States Code: the federal laws in force, arranged by subject. "4 U.S.C. § 8" means title 4, section 8. , section Section (§) The basic unit of the Code, marked §. Each section has a number within its title and is cited like "7 U.S.C. § 2012". 2012.
42 U.S.C. Chapter 6A · Public Health Service 1 section § 262 Regulation of biological products Shown